Preserving European Antibiotics: The Need for Sustainable R&D Funding
Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat infections, and...
top of page
‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.
It is a European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.
A project sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including the models, once the project has finished.
PRIMAVERA is part of the AMR Accelerator Programme.
 Scientist on Computer_edited_edited |
|---|
 Conference |
 Add a Title |
 icon_PrIMAVeRA_crop |
 Laboratory |
 Drug and Syringe |
 Girl at the Pediatrician |
 Pipetting Samples |
 hand shake_Inno4Vac KoM_Source Wix |
 Add a Title |
 Preventive services |
 Add a Title |
At a glance
Innovations to accelerate vaccine development and manufacture
TIMELINE
01.11.2021-30.11.2026
(5 Years)
COORDINATOR
European Vaccine Initiative (EVI)
FUNDER
Innovative Medicines Initiative 2 (IMI2) and European Federation of Pharmaceutical Industries and Associations (EFPIA)
FUNDING
€9.25 Mio
(€6.5 Mio from IMI2 and €2.75 Mio from EFPIA)
bottom of page